A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

PHASE3CompletedINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

January 17, 2025

Study Completion Date

March 7, 2025

Conditions
Obesity or Overweight
Interventions
DRUG

Cagrilintide

Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

DRUG

Semaglutide

Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

DRUG

Placebo Semaglutide

Participants will receive placebo matched to semaglutide

Trial Locations (22)

10048

National Taiwan University Hospital, Taipei

963-8851

Seino Internal Medicine Clinic, Koriyama-shi

242-0004

Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi

880-0034

Heiwadai Hospital, Miyazaki

565-0853

OCROM Clinic, Suita-shi

581-0011

Yao Tokushukai General Hospital, Yao-shi

468-0009

TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology, Aichi

113-8655

The University of Tokyo Hospital, Diabetes and Metabolic, Bunkyo-ku, Tokyo

260-0804

Akaicho Clinic, Chiba-shi, Chiba

101-0065

Suidoubashi Medical Clinic, Chiyoda-ku, Tokyo

103-0002

The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo

104-0061

Okabe Clinic, Chuo-ku, Tokyo

373-0036

Kawada Clinic, Gunma

311-0113

Naka Kinen Clinic, Ibaraki

020-8505

Iwate Medical University Uchimaru Medical Center, Division of Diabetes and Metabolism and Endocrine medicine, Numakunai

530-0001

Osaka NISHI-UMEDA Clinic, Osaka

004-0004

Shinsapporo Seiryou Hospital, General Clinical Department, Sapporo-shi, Hokkaido

983-0039

Shinden Higashi Clinic, Sendai-shi, Miyagi

103-0027

Tokyo-Eki Center-building Clinic, Tokyo

104-0031

Fukuwa Clinic, Tokyo

160-0008

ToCROM Clinic, Tokyo

192-0918

Minamino Cardiovascular Hospital, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY